scholarly journals Implication of Riyazat (Exercise) in Primary Dysmenorrhoea (Usr-E-Tams)

2021 ◽  
Vol 10 (01) ◽  
pp. 17-21
Author(s):  
Hafiz Iqtidar Ahmad ◽  
Keyword(s):  
Abdominal Pain ◽  
Side Effects ◽  
Pelvic Pain ◽  
Pharmacological Treatment ◽  
Pivotal Role ◽  
Regular Exercise ◽  
Hormonal Changes ◽  
Epithelial Tissues ◽  
Primary Dysmenorrhoea ◽  
Muscle Spasms

Dysmenorrhoea (usr-e-tams) is a usual gynaecological condition comprising of painful muscle spasms coming with menstruation, which in the absence of any fundamental irregularity or pathology, is known as primary dysmenorrhoea. Primary dysmenorrhoea is the nearly usual cyclical pelvic pain affecting the satisfaction of life. The relative incidence of primary dysmenorrhoea was reported to be within 20% and 90% in many societies. Studies have shown that regular exercise decreases dysmenorrhoea in women, which may be due to the effects of hormonal changes on uterine epithelial tissues or an enhancement in endorphin levels. It appears that exercise has pain-killing events that act in a non-particular way. Research has demonstrated that women with dysmenorrhoea have high degrees of prostaglandins, and hormones acknowledged to cause hampering abdominal pain. Exercise is a non-pharmacological treatment with the aim of reducing side effects commonly reported in association with NSAIDs, such as indigestion, headaches and drowsiness. Thus, diminution of pain may be due to consequences of hormonal changes on uterine epithelial tissues or an increase in endorphin levels. However, exercise has analgesic events that behave in a non-specific way and may be substituted for analgesics. Exercise may play a pivotal role in combating difficulties due to dysmenorrhoea. This article reviews the effects of exercise on dysmenorrhoea.

scholarly journals The association between cannabis use and outcome in pharmacological treatment for opioid use disorder

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Tea Rosic ◽  
Raveena Kapoor ◽  
Balpreet Panesar ◽  
Leen Naji ◽  
Darren B. Chai ◽  
...  
Keyword(s):  
Side Effects ◽  
Pharmacological Treatment ◽  
Addiction Treatment ◽  
Age Of Onset ◽  
Opioid Use Disorder ◽  
Cannabis Use ◽  
Self Report ◽  
Opioid Use ◽  
Differential Outcomes ◽  
Urine Drug

Abstract Background With the ongoing opioid crisis and policy changes regarding legalization of cannabis occurring around the world, it is necessary to consider cannabis use in the context of opioid use disorder (OUD) and its treatment. We aimed to examine (1) past-month cannabis use in patients with OUD, (2) self-reported cannabis-related side effects and craving, and (3) the association between specific characteristics of cannabis use and opioid use during treatment in cannabis users. Methods Participants receiving pharmacological treatment for OUD (n = 2315) were recruited from community-based addiction treatment clinics in Ontario, Canada, and provided information on past-month cannabis use (self-report). Participants were followed for 3 months with routine urine drug screens in order to assess opioid use during treatment. We used logistic regression analysis to explore (1) the association between any cannabis use and opioid use during treatment, and (2) amongst cannabis-users, specific cannabis use characteristics associated with opioid use. Qualitative methods were used to examine responses to the question: “What effect does marijuana have on your treatment?”. Results Past-month cannabis use was reported by 51% of participants (n = 1178). Any cannabis use compared to non-use was not associated with opioid use (OR = 1.03, 95% CI 0.87–1.23, p = 0.703). Amongst cannabis users, nearly 70% reported daily use, and half reported experiencing cannabis-related side effects, with the most common side effects being slower thought process (26.2%) and lack of motivation (17.3%). For cannabis users, daily cannabis use was associated with lower odds of opioid use, when compared  with occasional use (OR = 0.61, 95% CI 0.47–0.79, p < 0.001) as was older age of onset of cannabis use (OR = 0.97, 95% CI 0.94, 0.99, p = 0.032), and reporting cannabis-related side effects (OR = 0.67, 95% CI 0.51, 0.85, p = 0.001). Altogether, 75% of cannabis users perceived no impact of cannabis on their OUD treatment. Conclusion Past-month cannabis use was not associated with more or less opioid use during treatment. For patients who use cannabis, we identified specific characteristics of cannabis use associated with differential outcomes. Further examination of characteristics and patterns of cannabis use is warranted and may inform more tailored assessments and treatment recommendations.

scholarly journals A Case of Polyneuropathy Following a Single Dose of Diethylcarbamazine and Albendazole During Mass Administration of Drug - A Case Report

1970 ◽  
Vol 1 (1) ◽  
pp. 56-58
Author(s):  
SC Kohli ◽  
UK Shrestha ◽  
VM Alurkar ◽  
A Maskey ◽  
M Parajuli ◽  
...  
Keyword(s):  
Abdominal Pain ◽  
Single Dose ◽  
Case Report ◽  
Side Effects ◽  
World Health Organization ◽  
Mass Drug Administration ◽  
World Health ◽  
Medical Sciences ◽  
The World ◽  
Health Organization

The global program to eliminate Lymphatic Filariasis created by The World Health organization in 1997 is based on mass administration of single annual doses of diethylcarbamazine ( DEC) plus albendazole in non African regions and of albendazole plus ivermectin in Africa. The usual side effects of DEC treatment include fever, chills, arthralgia, headaches, nausea, and vomiting. Albendazole is associated with relatively few side effects consisting of occasional nausea, vomiting, abdominal pain, headache, reversible alopecia, elevated aminotransferases and rarely leucopenia and rash. We report a case of polyneuropathy in a young individual following DEC and albendazole during mass drug administration. Keywords: Albendazole; DEC; Polyneuropathy. DOI: http://dx.doi.org/10.3126/njms.v1i1.5800   Nepal Journal of Medical Sciences. 2012; 1(1): 56-58

scholarly journals Selenium and functional constipation in children

2016 ◽  
Vol 56 (2) ◽  
pp. 111
Author(s):  
Marlina Tanjung ◽  
Supriatmo Supriatmo ◽  
Melda Deliana ◽  
Ade Rachmat Yudiyanto ◽  
Atan Baas Sinuhaji
Keyword(s):  
Abdominal Pain ◽  
Placebo Group ◽  
Side Effects ◽  
Functional Constipation ◽  
Causative Factor ◽  
Gastrointestinal Diseases ◽  
Average Frequency ◽  
Stool Consistency ◽  
Significant Difference ◽  
Selenium Treatment

Background Constipation is a common problem in children, with approximately 90 to 95% of constipation cases having functional constipation. Oxidative stress may be a causative factor in gastrointestinal diseases, alleved by intervention with antioxidants. Selenium is an essential trace element and acts as a cofactor of gluthathione peroxidase, which protects membranes from oxidative damage.Objective To determine the effect of selenium on functional constipation in children.Methods We conducted a single-blind, randomized clinical trial from November to December 2012 at the Al-Kautsar Al-Akbar Islamic Boarding School in Medan, North Sumatra. Subjects were children aged 12 to 17 years with functional constipation, diagnosed according to the ROME III criteria. Patients were randomly allocated into either the selenium group (n=57) or the placebo group (n=57). Subjects were clinically evaluated for frequency of defecation, stool consistency, severity of abdominal pain, and side effects during the 2 weeks of treatment (days 7 and 14) and 1 week after treatment had stopped (day 21).Results A total of 114 subjects were eligible to participate. The average frequency of defecation observed on day 14 was 1.5 (SD 0.75) days per defecation (P=0.0001) in the selenium group and 2.4 (0.84) days per defecation in the placebo group, a statistically significant difference (P=0.0001). There was no significant difference in frequency of defecation on the 7th day of treatment. But after day 7, there were significant differences between the groups at days 14 and 21. Normal stool consistency was found in 45 subjects (78.9%) on day 7 and in 57 subjects (100%) on day 14 of treatment in the selenium group, significantly more than those in the placebo group (P<0.05). In placebo group, normal stool consistency was found in 27 subject (47.4%) with (P=0.001) on day 7 and in 38 subject (66.7%) on day 14 of treatment (P=0.0001). On day 14, the selenium group had significantly more subjects without pain than the placebo group [47 subjects (82.5%) vs. 10 subjects (17.5%), respectively (P=0.0001)]. Severity of abdominal pain after 14th day of treatment is without pain 47 subject (82.5%) and mild pain 10 subject (17.5%) (P=0.0001). We found no side effects of selenium treatment in our subjects.Conclusion Selenium is effective in improving clinically functional constipation, in terms of increased frequency of defecation, normalization of stool consistency, and less severe abdominal pain.

Pharmacological Treatment of Chronic Pelvic Pain

2020 ◽  
pp. 945-949
Author(s):  
Ashish Shetty ◽  
Oscar Morice ◽  
Sohier Elneil
Keyword(s):  
Pelvic Pain ◽  
Pharmacological Treatment ◽  
Chronic Pelvic Pain

scholarly journals Ovarian Torsion Presentation, Treatment and Iatrogenic Surgical Management

2021 ◽  
pp. 70-76
Author(s):  
Sheema Sabahath ◽  
Hussain Salah AL Sinan ◽  
Asalah Tariq Alsaigh ◽  
Rawan AlSalamah AlFadhli ◽  
Tahani Salman Al Mansour ◽  
...  
Keyword(s):  
Blood Flow ◽  
Abdominal Pain ◽  
Side Effects ◽  
Adverse Events ◽  
Surgical Intervention ◽  
Clinical Manifestations ◽  
Ovarian Torsion ◽  
Adult Females ◽  
Uterine Ligaments ◽  
Life Threatening

Ovarian torsion is among the gynecological life-threatening conditions that may require urgent surgical intervention among the appearance of clinical manifestations. The most common clinical manifestations include severe abdominal pain, nausea extending to vomiting. The ovarian torsion is not limited to children only. However, it can also occur in adult females, either pregnant or non-pregnant. The etiology of the disease tends to be related to the weakness of the uterine ligaments or malpositioning of it due to known and unknown causes. Despite that, the surgical intervention is needed to release the torsion. Sometimes, it can lead to adverse events or side effects such as decreased blood flow to the surrounding structures. Which by role may lead to unpleasant complications and clinical manifestations of hemorrhage and shock. In this article, we reviewed the topic of ovarian torsion from different aspects, including the definition, causes, clinical evaluation, and clinical management and its common complications.

Patients with Pain During Pregnancy

2016 ◽  
Author(s):  
Charles J. Fox ◽  
Alan D. Kaye ◽  
Elyse Cornett ◽  
Katherine Stammen ◽  
Michael Franklin
Keyword(s):  
Abdominal Pain ◽  
Back Pain ◽  
Pregnant Women ◽  
Pelvic Pain ◽  
Joint Laxity ◽  
The Body ◽  
Healthy Pregnancy ◽  
Pain Analgesics ◽  
Chronic Severe Pain ◽  
Anxiety Depression

Most women experience some degree of pain during pregnancy. Back pain occurs in about half of all pregnant women, with pain typically in the low back due to the physiologic changes in the body that occur with pregnancy, such as weight gain, changed center of gravity, increased ligament and joint laxity, and altered posture. Pelvic pain, leg cramps, and abdominal pain are all common among pregnant women. Many women who have pain during pregnancy are reluctant to use analgesics due to concerns about what the medications may do to their unborn child. Because of this, it is hypothesized that many women are either undertreated for pain or do not receive any treatment. Chronic, severe pain that is ineffectively treated is associated with hypertension, anxiety, and depression, all of which do not lead to a healthy pregnancy. A variety of interventional procedures are commonly performed during pregnancy that can safely alleviate pain. This review goes into detail about the types of pain treatments that are available to pregnant women and are safe and effective in alleviating pregnancy-related pain. Keywords: Pelvic pain, leg cramps, abdominal pain, hypertension, anxiety, depression, joint laxity, ligament laxity, back pain, analgesics, pregnancy

Pharmacological Treatment of ADHD

2021 ◽  
pp. 132-145
Author(s):  
Prateek Yadav
Keyword(s):  
Side Effects ◽  
Pharmacological Treatment ◽  
Psychosocial Treatments ◽  
First Choice

The pharmacological treatment for ADHD has been researched well and we have efficacious drugs. Drugs are the mainstay of treatment particularly for over 6 years of age. There are two broad classes of drugs that are used in the treatment, psychostimulants and non-stimulants. Transcranial current stimulation and neurofeedback are other mechanisms that have been tried. There are various formulations and doses available for each and only certain drugs are available in India. The various guidelines broadly put stimulant Methylphenidate as the first choice and recommend early shift to a longer acting formulation. Treatment, various comorbidities, and side-effects of these drugs have to be kept in mind and dealt accordingly. Further psychosocial treatments should be used concurrently to improve the outcome.

Sign in / Sign up

Export Citation Format

Share Document